FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376614030> ?p ?o ?g. }

• W4376614030 endingPage "14137" @default.
• W4376614030 startingPage "14130" @default.
• W4376614030 abstract "Abstract Background Pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF) can be used in pediatric patients. This study assessed the safety and efficacy of PEG‐rhG‐CSF as a primary prophylactic drug against neutropenia after chemotherapy in pediatric patients with solid tumors or non‐Hodgkin lymphoma (NHL). Patients and Methods This phase II study (between October 2020 and March 2022) enrolled pediatric patients with solid tumors or NHL treated with high‐intensity chemotherapy and with grade ≥3 myelosuppression for at least 14 days during chemotherapy. Prophylactic PEG‐rhG‐CSF was given at 100 μg/kg body weight (maximum total dosage of 6 mg) once 24–48 h following chemotherapy for two cycles. The primary endpoint was the incidence of PEG‐rhG‐CSF‐related adverse events (AEs). The key secondary endpoints were the rates of grade 3/4 neutropenia and febrile neutropenia (FN). Results This study included 160 pediatric patients with a median age of 6.22 (0.29, 18.00) years. Fifty‐eight patients (36.25%) were diagnosed with sarcoma. AEs potentially related to PEG‐rhG‐CSF included bone pain ( n = 32), fatigue ( n = 21), pain at the injection site ( n = 21), and myalgia ( n = 20). The rates of grade 3/4 neutropenia and FN during treatment were 57.28% and 29.45%, respectively. Conclusion PEG‐rhG‐CSF is well tolerated and effective in pediatric patients with solid tumors or NHL. These findings should be substantiated with further trials. Clinical Trial Registration ClinicalTrials.gov identifier: NCT04547829." @default.
• W4376614030 created "2023-05-17" @default.
• W4376614030 creator A5002572745 @default.
• W4376614030 creator A5004735532 @default.
• W4376614030 creator A5005036619 @default.
• W4376614030 creator A5008841145 @default.
• W4376614030 creator A5025137178 @default.
• W4376614030 creator A5026590331 @default.
• W4376614030 creator A5029241959 @default.
• W4376614030 creator A5030948225 @default.
• W4376614030 creator A5036546912 @default.
• W4376614030 creator A5036663316 @default.
• W4376614030 creator A5041822883 @default.
• W4376614030 creator A5047365731 @default.
• W4376614030 creator A5055585688 @default.
• W4376614030 creator A5057973270 @default.
• W4376614030 creator A5059077734 @default.
• W4376614030 creator A5063584306 @default.
• W4376614030 creator A5087068082 @default.
• W4376614030 creator A5089183088 @default.
• W4376614030 creator A5091948937 @default.
• W4376614030 date "2023-05-15" @default.
• W4376614030 modified "2023-09-24" @default.
• W4376614030 title "A multicenter phase <scp>II</scp> trial of primary prophylactic <scp>PEG‐rhG‐CSF</scp> in pediatric patients with solid tumors and <scp>non‐Hodgkin</scp> lymphoma after chemotherapy: An interim analysis" @default.
• W4376614030 cites W1899606784 @default.
• W4376614030 cites W2030045357 @default.
• W4376614030 cites W2069880747 @default.
• W4376614030 cites W2076804008 @default.
• W4376614030 cites W2078287340 @default.
• W4376614030 cites W2099191657 @default.
• W4376614030 cites W2519937445 @default.
• W4376614030 cites W2528477403 @default.
• W4376614030 cites W2772503094 @default.
• W4376614030 cites W2887657259 @default.
• W4376614030 cites W3006927664 @default.
• W4376614030 cites W3032368587 @default.
• W4376614030 cites W3040325970 @default.
• W4376614030 cites W3098256180 @default.
• W4376614030 cites W3123878640 @default.
• W4376614030 cites W3124176434 @default.
• W4376614030 cites W3128936999 @default.
• W4376614030 cites W3164124115 @default.
• W4376614030 cites W3165262247 @default.
• W4376614030 cites W3179034084 @default.
• W4376614030 cites W3179659064 @default.
• W4376614030 cites W3194102898 @default.
• W4376614030 cites W3203643355 @default.
• W4376614030 cites W3208898602 @default.
• W4376614030 cites W3209988646 @default.
• W4376614030 cites W3212218503 @default.
• W4376614030 cites W3572614 @default.
• W4376614030 cites W389520367 @default.
• W4376614030 cites W4200197704 @default.
• W4376614030 cites W4210414958 @default.
• W4376614030 cites W4210465565 @default.
• W4376614030 cites W4225762897 @default.
• W4376614030 cites W4226368000 @default.
• W4376614030 cites W4376614030 @default.
• W4376614030 doi "https://doi.org/10.1002/cam4.6079" @default.
• W4376614030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37183837" @default.
• W4376614030 hasPublicationYear "2023" @default.
• W4376614030 type Work @default.
• W4376614030 citedByCount "1" @default.
• W4376614030 countsByYear W43766140302023 @default.
• W4376614030 crossrefType "journal-article" @default.
• W4376614030 hasAuthorship W4376614030A5002572745 @default.
• W4376614030 hasAuthorship W4376614030A5004735532 @default.
• W4376614030 hasAuthorship W4376614030A5005036619 @default.
• W4376614030 hasAuthorship W4376614030A5008841145 @default.
• W4376614030 hasAuthorship W4376614030A5025137178 @default.
• W4376614030 hasAuthorship W4376614030A5026590331 @default.
• W4376614030 hasAuthorship W4376614030A5029241959 @default.
• W4376614030 hasAuthorship W4376614030A5030948225 @default.
• W4376614030 hasAuthorship W4376614030A5036546912 @default.
• W4376614030 hasAuthorship W4376614030A5036663316 @default.
• W4376614030 hasAuthorship W4376614030A5041822883 @default.
• W4376614030 hasAuthorship W4376614030A5047365731 @default.
• W4376614030 hasAuthorship W4376614030A5055585688 @default.
• W4376614030 hasAuthorship W4376614030A5057973270 @default.
• W4376614030 hasAuthorship W4376614030A5059077734 @default.
• W4376614030 hasAuthorship W4376614030A5063584306 @default.
• W4376614030 hasAuthorship W4376614030A5087068082 @default.
• W4376614030 hasAuthorship W4376614030A5089183088 @default.
• W4376614030 hasAuthorship W4376614030A5091948937 @default.
• W4376614030 hasBestOaLocation W43766140301 @default.
• W4376614030 hasConcept C126322002 @default.
• W4376614030 hasConcept C141071460 @default.
• W4376614030 hasConcept C197934379 @default.
• W4376614030 hasConcept C203092338 @default.
• W4376614030 hasConcept C2776694085 @default.
• W4376614030 hasConcept C2777063308 @default.
• W4376614030 hasConcept C2777767877 @default.
• W4376614030 hasConcept C2778850193 @default.
• W4376614030 hasConcept C2779338263 @default.
• W4376614030 hasConcept C535046627 @default.
• W4376614030 hasConcept C71924100 @default.
• W4376614030 hasConcept C90924648 @default.
• W4376614030 hasConceptScore W4376614030C126322002 @default.

• next